Circulation
Cholesterol care gets aggressive: 2026 guideline urges faster escalation beyond statins
Clinical Takeaway: Start lipid-lowering therapy earlier using PREVENT risk estimates, aim for lower LDL-C goals (often <55 mg/dL in high-risk patients), and escalate quickly beyond statins with ezetimibe, PCSK9 inhibitors, inclisiran, or bempedoic acid to close treatment gaps.
What’s changed
The 2026 guideline introduces several practice-shifting updates that move beyond the 2018 approach:
- New risk calculator and lower treatment thresholds: The PREVENT equations replace pooled cohort equations, and lipid-lowering therapy can now be considered starting at a 10-year risk of ≥3%, expanding eligibility for earlier treatment.
- Return to LDL-C and non–HDL-C goals: Absolute targets are re-emphasized alongside percent reduction, with more aggressive goals (eg, <55 mg/dL in very high-risk ASCVD).
- Routine Lp(a) testing recommended: A one-time Lp(a) measurement is now advised for all adults, with elevated levels prompting intensified therapy.
- ApoB incorporated for residual risk: ApoB measurement is endorsed to guide further treatment when LDL-C goals are met but risk remains elevated.
- Broader and earlier use of combination therapy: Stronger emphasis on adding ezetimibe, PCSK9 inhibitors, inclisiran, or bempedoic acid rather than relying on statins alone.
- Integration of newer drugs: Inclisiran (siRNA) and bempedoic acid are formally incorporated into treatment pathways; olezarsen is introduced for familial chylomicronemia.
- CAC-guided decision-making expanded: Coronary artery calcium scoring is elevated to help refine both initiation and intensity of therapy.
- Dietary supplements discouraged: Supplements are explicitly not recommended for lipid lowering due to lack of benefit.
The 2026 ACC/AHA multisociety guideline on dyslipidemia replaces the 2018 cholesterol guideline and reframes lipid management around lifetime exposure to atherogenic particles, earlier treatment initiation, and more aggressive LDL-C lowering. The authors highlight that “treating dyslipidemia earlier” is key to reducing cumulative cardiovascular risk.
A major shift is adoption of the PREVENT equations for 10- and 30-year risk assessment. These more contemporary models enable treatment consideration at lower estimated risk thresholds, with lipid-lowering therapy now reasonable starting at a 10-year risk ≥3%. The guideline also formalizes a “CPR” approach—Calculate, Personalize, Reclassify—using risk enhancers and coronary artery calcium (CAC) scoring to refine decisions.
Treatment goals are back in focus. LDL-C targets are now <100 mg/dL for moderate risk, <70 mg/dL for high risk, and <55 mg/dL for very high–risk ASCVD—paired with non–HDL-C targets and continued emphasis on ≥30%–50% LDL reductions depending on risk. This return to goal-directed therapy is a notable evolution from prior frameworks centered primarily on statin intensity.
Statins remain the foundation of therapy, but combination treatment is strongly emphasized. For patients not at goal on maximally tolerated statins, ezetimibe is first-line add-on, followed by PCSK9 monoclonal antibodies, bempedoic acid, or inclisiran based on clinical context and patient preference. PCSK9 inhibitors and inclisiran can lower LDL-C by ~50% or more, while bempedoic acid offers an oral option especially for statin intolerance.
The guideline also broadens the role of newer and specialty therapies. Inclisiran is positioned as a practical alternative for patients who prefer infrequent dosing, and olezarsen (an apoC-III inhibitor) is introduced for familial chylomicronemia syndrome to reduce triglycerides and pancreatitis risk. Icosapent ethyl remains the only triglyceride-lowering drug with proven ASCVD event reduction when added to statins.
Two biomarkers take center stage. Lipoprotein(a) should now be measured at least once in all adults, with elevated levels used to intensify LDL-lowering strategies. Apolipoprotein B is recommended to uncover residual risk, particularly in patients with diabetes, elevated triglycerides, or discordant lipid values.
Hypertriglyceridemia management reinforces statins as first-line for ASCVD risk reduction, with fibrates or omega-3 therapies reserved for severe elevations (≥500–1000 mg/dL) to prevent pancreatitis. Notably, dietary supplements are explicitly discouraged for lipid lowering due to lack of efficacy.
Overall, the guideline signals a more proactive, combination-driven approach. As the authors emphasize, addressing dyslipidemia earlier and more intensively “reduces lifelong exposure” to atherogenic lipoproteins—potentially reshaping prevention across the lifespan.
Source: Blumenthal RS, et al. (2026, April 28). Circulation. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines